3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Ameloblastoma
1
Interventions
fludarabine
3
Cyclophosphamide
3
Busulfan
2
venetoclax
1
trametinib
1
luspatercept
1
gilteritinib
1
dabrafenib
1
Whole-Body Irradiation
1
Vancomycin
1
Thiotepa
1
Teicoplanin
1
Tacrolimus
1
Stem Cell Transplantation
1
Rituximab
1
Radiosurgery
1
Ofloxacin
1
NF protocol
1
Mycophenolic Acid
1
Metronidazole
1
Meropenem
1
Kidney Transplantation
1
Granulocyte Colony-Stimulating Factor
1
Genetic Testing
1
Cytarabine
1
Complementary Therapies
1
Ciprofloxacin
1
Ceftazidime
1
Cefepime
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Hematologic Neoplasms
×
dabrafenib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled